Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S
Department of Nuclear Medicine, University of Louvain Medical School, Brussels, Belgium.
J Nucl Med. 1996 Jun;37(6):916-22.
The biodistribution of 111In-pentetreotide was assessed in patients with gastroenteropancreatic (GEP) neuroendocrine tumors or lymphoma and in control patients and analyzed as a function of scanning time, presence or absence of tumor uptake, tumor type and previous octreotide treatment.
Patients underwent imaging 4 and 24 hr after injection of approximately 200 MBq 111In-pentetreotide. The frequency of organ visualization was assessed on planar views. Total organ and tumor uptake (% injected dose [ID]) was determined using the geometric mean method and regional tissue uptake (% ID/100 ml) by semiquantitative SPECT.
Liver, spleen, kidneys and urinary bladder were visualized in all patients. Thyroid, bowel and pituitary were more often visualized at 24 hr than at 4 hr. Activity in the gallbladder, breast, ureters and ascites was only occasionally observed. Total liver, spleen and thyroid uptake was stable over time, whereas kidney activity decreased slightly. At 24 hr, regional uptake was threefold lower in the liver than in the spleen or kidneys and was similar in the three groups. In patients with long-term octreotide therapy, a positive correlation was found between the duration of octreotide therapy and liver or spleen uptake. Total and regional tumor uptake showed high intraindividual and interindividual variations. Total tumor activity was stable over 24 hr in patients with GEP and decreased in those with lymphoma. The mean regional tumor uptake was 10-fold lower in patients with lymphoma than in those with GEP. Cold octreotide injected 24 hr after tracer administration did not result in any displacement of organ and tumor activity.
Organ uptake seems not to be influenced by the presence of 111In-pentetreotide-positive lesions or by tumor type. Tumor uptake is highly variable among patients and clearly lower in patients with lymphoma than in those with GEP. The widespread of uptake values in tumors indicates that radiotherapy using radiolabeled somatostatin analogs may not be applicable to all patients with 111In-pentetreotide-positive tumors.
评估了111铟-喷替肽在胃肠胰（GEP）神经内分泌肿瘤或淋巴瘤患者及对照患者中的生物分布，并根据扫描时间、有无肿瘤摄取、肿瘤类型和既往奥曲肽治疗情况进行分析。
患者在注射约200MBq的111铟-喷替肽后4小时和24小时进行成像。通过平面视图评估器官显影频率。使用几何平均法确定总器官和肿瘤摄取（注射剂量百分比[ID]），并通过半定量SPECT确定区域组织摄取（ID/100ml百分比）。
所有患者的肝脏、脾脏、肾脏和膀胱均显影。甲状腺、肠道和垂体在24小时时比4小时时更常显影。胆囊、乳腺、输尿管和腹水中的活性仅偶尔观察到。肝脏、脾脏和甲状腺的总摄取随时间稳定，而肾脏活性略有下降。在24小时时，肝脏的区域摄取比脾脏或肾脏低三倍，且三组相似。在长期接受奥曲肽治疗的患者中，发现奥曲肽治疗持续时间与肝脏或脾脏摄取之间存在正相关。总肿瘤摄取和区域肿瘤摄取显示出较高的个体内和个体间差异。GEP患者的总肿瘤活性在24小时内稳定，淋巴瘤患者的总肿瘤活性下降。淋巴瘤患者的平均区域肿瘤摄取比GEP患者低10倍。在示踪剂给药后24小时注射冷奥曲肽并未导致器官和肿瘤活性的任何移位。
器官摄取似乎不受111铟-喷替肽阳性病变的存在或肿瘤类型的影响。肿瘤摄取在患者之间高度可变，淋巴瘤患者的肿瘤摄取明显低于GEP患者。肿瘤摄取值的广泛分布表明，使用放射性标记的生长抑素类似物进行放射治疗可能不适用于所有111铟-喷替肽阳性肿瘤患者。
